I am of the opinion, that with the two upcoming conferences PYC are attending in the US, (2nd May, and 4 - 8th May), shareholders may see a positive uptick in the way the market values PYC's RP11 program.
I am suggesting this based on efficacy data which is scheduled for presentation at these conferences. As the number of patients, within the SAD/MAD extended dosing study has increased over time, due to eligible patients choosing to opt in, efficacy data has also been growing. Primarily this is because we simply have more patients in the extended study and secondly, (very importantly), more of those patients would be hitting significant and more meaningful milestones in terms of efficacy data accumulated.
In effect, the clinical data we are about to see may reshape the forward looking landscape as PYC prepare for their early June meeting with the FDA to gain clarity on alignment for a possible accelerated P2/P3 registrational trial.
Best wishes to all
PYC Price at posting:
$1.03 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)